Cargando…
Surgical Treatment of Metastatic Bone Disease—When Decisions at End-of-Life Really Makes the Difference
Autores principales: | Sørensen, Michala Skovlund, Petersen, Michael Mørk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197483/ https://www.ncbi.nlm.nih.gov/pubmed/34070329 http://dx.doi.org/10.3390/cancers13112581 |
Ejemplares similares
-
Extent of Surgery Does Not Influence 30-Day Mortality in Surgery for Metastatic Bone Disease: An Observational Study of a Historical Cohort
por: Sørensen, Michala Skovlund, et al.
Publicado: (2016) -
Surgical Treatment of Metastatic Bone Disease in the Appendicular Skeleton: A Population-Based Study
por: Ladegaard, Thea Hovgaard, et al.
Publicado: (2022) -
Dislocation rate after hip arthroplasty due to metastatic bone disease: a retrospective cohort study evaluating the postoperative dislocation risk across different articulating solutions
por: ILJAZI, Afrim, et al.
Publicado: (2023) -
Fully constrained acetabular liner vs. dual mobility hip joint in the surgical treatment of metastatic bone disease of the hip: study protocol for a randomized, open-label, two-arm, non-inferiority trial evaluating the post-operative hip dislocation rate
por: Iljazi, Afrim, et al.
Publicado: (2023) -
Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities
por: Sørensen, Michala Skovlund, et al.
Publicado: (2021)